WallStreetZenWallStreetZen

NYSE: DOCS
Doximity Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DOCS

Based on 22 analysts offering 12 month price targets for Doximity Inc

Min Forecast
$18.00-9.37%
Avg Forecast
$31.96+60.9%
Max Forecast
$65.00+227.29%

Should I buy or sell DOCS stock?

Based on 22 analysts offering ratings for Doximity Inc.

Buy
Strong Buy
9 analysts 40.91%
Buy
3 analysts 13.64%
Hold
10 analysts 45.45%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although DOCS's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates DOCS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their DOCS stock forecasts and price targets.

DOCS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-15
lockedlocked$00.00+00.00%2026-05-15
lockedlocked$00.00+00.00%2026-05-14
lockedlocked$00.00+00.00%2026-05-14
lockedlocked$00.00+00.00%2026-05-14
JP Morgan
Top 24%
77
HoldMaintains$28.00+40.99%2026-05-14
Truist Securities
Bottom 1%
1
HoldReiterates$19.00-4.33%2026-05-14
Wells Fargo
Bottom 4%
4
HoldDowngrades$18.00-9.37%2026-05-14
BMO Capital
Top 30%
71
HoldMaintains$20.00+0.70%2026-05-14
Mizuho
Bottom 4%
4
HoldMaintains$26.00+30.92%2026-05-14

1 of 3

Forecast return on equity

Is DOCS forecast to generate an efficient return?

Company
36.81%
Industry
23.47%
Market
170.3%
DOCS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DOCS forecast to generate an efficient return on assets?

Company
31.15%
Industry
16.96%
DOCS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DOCS earnings per share forecast

What is DOCS's earnings per share in the next 3 years based on estimates from 24 analysts?

Avg 1 year Forecast
$1.53+45.32%
Avg 2 year Forecast
$1.68+60.24%
Avg 3 year Forecast
$1.91+82.28%
DOCS's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

DOCS revenue forecast

What is DOCS's revenue in the next 3 years based on estimates from 25 analysts?

Avg 1 year Forecast
$689.6M+6.93%
Avg 2 year Forecast
$739.2M+14.62%
Avg 3 year Forecast
$791.5M+22.73%
DOCS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DOCS earnings growth forecast

How is DOCS forecast to perform vs Health Information Services companies and vs the US market?

Company
21.61%
Industry
28.96%
Market
33.32%
DOCS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
DOCS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
DOCS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

DOCS revenue growth forecast

How is DOCS forecast to perform vs Health Information Services companies and vs the US market?

Company
7.02%
Industry
8.4%
Market
13.73%
DOCS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DOCS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DOCS vs Health Information Service Stocks

TickerPricePrice TargetUp/downsideConsensus
DOCS$19.86$31.96+60.90%Buy
WAY$19.21$33.38+73.74%Strong Buy
MMED$11.63$21.60+85.73%Strong Buy
TXG$23.98$24.20+0.92%Buy
HNGE$54.74$64.91+18.58%Strong Buy
View Top Health Information Service Stocks

Doximity Stock Forecast FAQ

Is Doximity Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 22 Wall Street analysts covering (NYSE: DOCS) stock is to Buy DOCS stock.

Out of 22 analysts, 9 (40.91%) are recommending DOCS as a Strong Buy, 3 (13.64%) are recommending DOCS as a Buy, 10 (45.45%) are recommending DOCS as a Hold, 0 (0%) are recommending DOCS as a Sell, and 0 (0%) are recommending DOCS as a Strong Sell.

If you're new to stock investing, here's how to buy Doximity stock.

What is DOCS's earnings growth forecast for 2027-2029?

(NYSE: DOCS) Doximity's forecast annual earnings growth rate of 21.61% is not forecast to beat the US Health Information Services industry's average forecast earnings growth rate of 28.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.32%.

Doximity's earnings in 2026 is $196,051,000.On average, 24 Wall Street analysts forecast DOCS's earnings for 2027 to be $279,044,457, with the lowest DOCS earnings forecast at $231,186,842, and the highest DOCS earnings forecast at $330,266,917. On average, 20 Wall Street analysts forecast DOCS's earnings for 2028 to be $307,682,219, with the lowest DOCS earnings forecast at $252,692,595, and the highest DOCS earnings forecast at $366,749,890.

In 2029, DOCS is forecast to generate $349,998,811 in earnings, with the lowest earnings forecast at $301,080,538 and the highest earnings forecast at $385,951,455.

What is DOCS's revenue growth forecast for 2027-2029?

(NYSE: DOCS) Doximity's forecast annual revenue growth rate of 7.02% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 8.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.73%.

Doximity's revenue in 2026 is $644,863,000.On average, 25 Wall Street analysts forecast DOCS's revenue for 2027 to be $126,104,906,170, with the lowest DOCS revenue forecast at $119,040,558,995, and the highest DOCS revenue forecast at $135,819,069,307. On average, 21 Wall Street analysts forecast DOCS's revenue for 2028 to be $135,173,530,981, with the lowest DOCS revenue forecast at $123,550,183,674, and the highest DOCS revenue forecast at $154,589,056,211.

In 2029, DOCS is forecast to generate $144,737,739,039 in revenue, with the lowest revenue forecast at $130,808,375,219 and the highest revenue forecast at $158,882,891,875.

What is DOCS's forecast return on assets (ROA) for 2027-2029?

(NYSE: DOCS) forecast ROA is 31.15%, which is higher than the forecast US Health Information Services industry average of 16.96%.

What is DOCS's Price Target?

According to 22 Wall Street analysts that have issued a 1 year DOCS price target, the average DOCS price target is $31.96, with the highest DOCS stock price forecast at $65.00 and the lowest DOCS stock price forecast at $18.00.

On average, Wall Street analysts predict that Doximity's share price could reach $31.96 by May 15, 2027. The average Doximity stock price prediction forecasts a potential upside of 60.9% from the current DOCS share price of $19.86.

What is DOCS's Earnings Per Share (EPS) forecast for 2027-2029?

(NYSE: DOCS) Doximity's current Earnings Per Share (EPS) is $1.05. On average, analysts forecast that DOCS's EPS will be $1.53 for 2027, with the lowest EPS forecast at $1.26, and the highest EPS forecast at $1.81. On average, analysts forecast that DOCS's EPS will be $1.68 for 2028, with the lowest EPS forecast at $1.38, and the highest EPS forecast at $2.01. In 2029, DOCS's EPS is forecast to hit $1.91 (min: $1.65, max: $2.11).

What is DOCS's forecast return on equity (ROE) for 2027-2029?

(NYSE: DOCS) forecast ROE is 36.81%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.